Governance Documents

The Board of Directors of GI Dynamics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Management Team


Scott Schorer, President and Chief Executive Officer

Scott brings over 20 years of executive experience in the medical device industry, having both founded and helmed numerous companies in the healthcare space.

After graduating from Dartmouth College with Bachelor of Arts and Bachelor of Engineering degrees, Scott began his career as an infantry officer in the 82nd Airborne Division.

Following his military service, he began his medical device career as a sales representative for a surgical distributor. After identifying a need in the healthcare supply chain space, he co-founded and led CentriMed before the company was acquired by Global Healthcare Exchange. Scott next founded and led Innovative Spinal Technologies for eight years before the company was sold. He led the $100m Americas geography of Systagenix, a private equity acquisition of the J&J Advanced Wound Care Division.

More recently, Scott has served as a president and consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He has raised over $120m in public and private equity investments and also the co-inventor of six patents.

Dave Bruce, Director of Finance

Dave has been with GI Dynamics, serving on the finance team since October 2016. He previously served as Accounting Manager at Nutraclick LLC, and prior to that he was a consultant at Triton Resources. During his time with Triton, he acted as Controller for several companies in the biotechnology industry, including GNS Healthcare, Broad Institute, Stromedix and Daktari Diagnostics.

Dave has more than 15 years of accounting experience in the pharmaceutical, health and wellness, and fast casual restaurant industries, and holds both a BS in Accounting and an MBA with a concentration in Finance from Northeastern University.

Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.


Daniel J. Moore (Chairman)

Daniel Moore is Chairman of the Board for LivaNova [NASDAQ: LIVN] and also chairs the board of BrainScope Company, Inc. Mr. Moore previously held the position as president and chief executive officer of Cyberonics [NASDAQ: CYBX] from 2007 to 2015, when the company merged with Sorin to form LivaNova. Mr. Moore joined Cyberonics after 18 years at Boston Scientific [NYSE: BSX] where he was the president of InterContinental. He also serves on the boards of the Epilepsy Foundation of America, BioHouston and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering.

Prior company boards include TriVascular [NASDAQ: TRIV] which was sold to Endologix and Topera which was sold to Abbott. He also served on the boards of the Medical Device Manufacturers Association (past-Chair), Medical Device Innovation Consortium, the Epilepsy Foundation of Texas (past- Chair) and Smiling Kids Inc.


Dr. Oern Stuge

Dr. Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.


Timothy J. Barberich

Timothy Barberich has nearly 40 years’ experience in pharmaceutical and medical device companies, in technical, sales, marketing and management positions, including chief executive officer and chairman of the board. Mr. Barberich is a founder and former chief executive officer and chairman of Sepracor, Inc., now known as Sunovion Pharmaceuticals, a research-based pharmaceutical company which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009.

Mr. Barberich is currently chairman and chief executive officer of BioNevia Pharmaceuticals, Inc. He also serves on the board of directors of HeartWare International, Inc. [NASDAQ: HTWR], Verastem Inc. [NASDAQ: VSTM], Tokai Pharmaceuticals [NASDAQ: TKAI], Neurovance, Inc, and Mirimmune, Inc.


Juliet Thompson

Ms. Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dyanmics, Thompson also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.